他莫昔芬与芳香化酶抑制剂对凝血酶生成的差异化影响:前瞻性HEMOBREAST队列
该前瞻性队列纳入107例局限性乳腺癌女性,分别启动他莫昔芬(n=42)或芳香化酶抑制剂(n=65)治疗,比较基线及治疗10-16周后凝血酶生成等替代止血标志物的变化。他莫昔芬使用者内源性凝血酶潜力和凝血酶峰值升高,芳香化酶抑制剂使用者未见升高。
要点
- 他莫昔芬使用者内源性凝血酶潜力较基线升高+86 nM×min(95%CI 30-142),凝血酶峰值升高+33 nM(95%CI 21-45)。
- 芳香化酶抑制剂使用者内源性凝血酶潜力变化+44 nM×min(95%CI -4至93),凝血酶峰值+7 nM(95%CI -3至17),未达统计学显著。
- 他莫昔芬使用者归一化血栓调节蛋白敏感性比值升高+0.26(95%CI 0.19-0.33),芳香化酶抑制剂使用者+0.02(95%CI -0.03至0.07)。
核心结论
- 他莫昔芬相关的凝血酶生成增加与其已知的静脉血栓栓塞风险增加相一致,而芳香化酶抑制剂似乎不影响止血,提示缺乏相关的静脉血栓栓塞风险。
研究设计与样本
- 前瞻性队列研究,纳入107例局限性乳腺癌女性,启动他莫昔芬治疗42例、芳香化酶抑制剂治疗65例,于治疗前及治疗开始后10-16周测量凝血酶生成及其对血栓调节蛋白或活化蛋白C的敏感性及特定凝血参数。
- 试验注册号为NCT03381963。
主要发现
- 与基线相比,他莫昔芬使用者内源性凝血酶潜力升高+86 nM×min(95%CI 30-142),凝血酶峰值升高+33 nM(95%CI 21-45);芳香化酶抑制剂使用者内源性凝血酶潜力变化+44 nM×min(95%CI -4至93),凝血酶峰值+7 nM(95%CI -3至17)。
- 归一化血栓调节蛋白敏感性比值在他莫昔芬使用者升高+0.26(95%CI 0.19-0.33),在芳香化酶抑制剂使用者变化+0.02(95%CI -0.03至0.07)。
- 他莫昔芬使用者血浆纤维蛋白原、抗凝血酶、蛋白C和组织因子途径抑制物水平降低,游离蛋白S升高;芳香化酶抑制剂使用者未见这些变化。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Tamoxifen and aromatase inhibitors (AIs) are potent antitumoral agents against breast cancer. Tamoxifen increases the risk of venous thromboembolism (VTE), but the influence of AIs on the risk of VTE remains unclear. To inform clinical decisions, we evaluated associations of tamoxifen or AIs with changes of surrogate hemostatic biomarkers. This prospective cohort included 107 women with localized breast cancer starting tamoxifen (n = 42) or an AI (n = 65). Thrombin generation (CAT) its sensitivity to thrombomodulin (TM) or activated protein C (APC), and specific coagulation parameters, were measured before and 10-16 weeks after initiation of treatmen Compared with baseline, endogenous thrombin potential and thrombin peak increased in tamoxifen users (+86 nM × min; 95% confidence interval [CI], 30-142; and +33 nM; 95% CI, 21-45) but not in AI users (n = 65; +44 nM × min; 95% CI, -4 to 93; and +7 nM; 95% CI, -3 to 17). Normalized TM sensitivity ratios increased with tamoxifen (+0.26; 95% CI, 0.19-0.33y) but not with AI (+0.02; 95% CI, -0.03 to 0.07). Plasma levels of fibrinogen, antithrombin, protein C, and Tissue Factor Pathway Inhibitor decreased, and free protein S increased with tamoxifen but not with AIs. The observed shift toward increased coagulability associated with tamoxifen is in line with its known increased risk of VTE. In contrast, AIs do not appear to impact hemostasis, suggesting a lack of associated VTE risk. The trial was registered at www.clinicaltrials.gov as #NCT03381963.
引用
- Blondon M, Bodmer A, Thouvenin L, et al. Differential impact of tamoxifen and aromatase inhibitors on thrombin generation: the prospective HEMOBREAST cohort. Blood Adv. 2022. PMID: 35086148. doi:10.1182/bloodadvances.2021006623
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。